-
Alternative_name
(1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl)diphosphonic acid; NDC-zoledronate; zoledronate; Zometa; Reclast ; CGP 42446; CGP42446A; ZOL 446
-
Description
Zoledronic acid is a third-generation bisphosphonate that inhibits the prenylation of GTPases critical to the signaling events related to osteoclast-mediated bone resorption. It displays high affinity for hydroxyapatite (Ki = 3.47 μM) and binds directly to mineralized bone where it decreases bone resorption by inhibiting osteoclast proliferation and inducing osteoclast apoptosis. At micromolar concentrations, zoledronic acid demonstrates antitumor effects in vitro against breast, prostate, and myeloma cancer cells by inducing cytostasis and prevents bone metastases through its inhibitory effects on adhesion molecules, tumor cell invasion, and angiogenesis. Zoledronic acid has been used in the treatment of osteoporosis, Paget’s disease, metastatic bone disease, multiple myeloma, hypercalcemia of malignancy, and skeletal-related events associated with metastatic castrate-resistant prostate cancer.
-
CAS Number
165800-06-6
-
Structure Available
Yes
-
Salt Form
No
-
Molecular Formula
C₅H₁₂N₂O₈P₂
-
Molecular Weight
290.1
-
Cell Permeable
Yes
-
Purity
≥98%
-
Solubilities
PBS (~ 1.6 mg/ml)
-
Handling
Protect from air and moisture
-
Tag Line
A specific inhibitor of osteoclast-mediated bone resporption
-
Storage Condition
-20°C
-
Shipping Condition
gel pack
-
Shelf Life
36 months
-
MDL Number
MFCD08448695
-
PubChem CID
121586
-
-
SMILES
C1=CN(C=N1)CC(O)(P(=O)(O)O)P(=O)(O)O.O
-
InChi
InChI=1S/C5H10N2O7P2.H2O/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7;/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14);1H2
-
InChi Key
FUXFIVRTGHOMSO-UHFFFAOYSA-N
-
-
MSDS Available
Yes
